ASH 2023 | Dose escalation of RO7283420, a HLA-A2-WT1 CD3 T-cell bispecific antibody, in R/R AML
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, discusses the findings and limitations of the Phase I dose-escalation study (NCT04580121), which investigated the safety, tolerability, pharmacokinetics, anti-drug antibodies, and anti-leukemic activity of RO7283420, a bispecific antibody targetting WT1 and CD3 antigens on the surface of acute myeloid leukemia (AML) cells. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Pfizer, Takeda, Ichnos Sciences, AvenCell, Incyte Biosciences, Molecular Partners, AbbVie, Autolus, advesya (CanCell Therapeutics), Genmab US, Interius BioTherapeutics, Nektar Therapeutics, Orbital Therapeutics, Sanofi, Scare
Honoraria: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Pfizer, Takeda, Ichnos Sciences, AvenCell, Incyte Biosciences, Molecular Partners, AbbVie, Autolus, advesya (CanCell Therapeutics), Genmab US, Interius BioTherapeutics, Nektar Therapeutics, Orbital Therapeutics, Sanofi, Scare
Research Funding: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Seagen, Takeda, Molecular Partners
Speakers Bureau: Janssen, Roche, BMS/Celgene, Novartis, Gilead/Kite, Pfizer, AstraZeneca, GSK, LAWG, Springer Healthcare
Travel Support: Roche, Gilead/Kite, Pfizer
